Further development is needed in treating narcolepsy, a sleep disorder that disrupts the brain’s ability to regulate sleep-wake cycles, causing persistent sleepiness throughout the day.
What is the purpose of the Sparkle 1501 Study?
This clinical study is testing an investigational drug (TAK-994) to see how safe and tolerable it is and how it affects a person’s narcolepsy symptoms.
Is study participation an option for me?
You may qualify if you:
- Are 18–65 years old
- Have been diagnosed with narcolepsy with or without cataplexy
- Experience excessive daytime sleepiness
- Have narcolepsy with cataplexy and experience more than or equal to 4 partial or complete episodes of cataplexy/week
- Are willing to stop taking narcolepsy and cataplexy medications during study participation
- Meet additional requirements as determined by a screening process
A study doctor and staff can explain to you in greater detail other requirements and eligibility criteria you would have to meet to participate in the study. Travel support and compensation for study participation may be available.
To learn more about the Sparkle 1501 Study and to see if you may qualify, visit http://bit.ly/2PsEyEm.